Study of GlecaprevirPibrentasvir to Improve Symptoms and Functioning in Adults with Post-traumatic Stress Disorder

What this Trial Is About

Researchers are evaluating glecaprevirpibrentasvir GLEPIB, a direct-acting antiviral originally used to treat chronic hepatitis C infection, for its potential to improve symptoms in people with posttraumatic stress disorder PTSD who do not have hepatitis C. This double-blind randomized placebo-controlled trial aims to determine if GLEPIB can reduce PTSD symptoms and improve daily functioning, while also assessing the safety and tolerability of this treatment for PTSD. In this study, 92 participants diagnosed with PTSD will be randomly assigned to receive either GLEPIB or a placebo. Those receiving GLEPIB will take 3 oral tablets daily 100 mg glecaprevir and 40 mg pibrentasvir for 8 weeks. The placebo group will take matching inactive tablets for the same duration. Participants and researchers will not know which treatment is being given to ensure unbiased results. Throughout the 8-week treatment period, participants will be evaluated using the Clinical Administered Post-Traumatic Stress Disorder Scale version 5 CAPS-5 to measure changes in PTSD symptoms, and the World Health Organization Disability Assessment Schedule WHODAS to assess functioning. Safety and tolerability will be monitored closely. The total study participation involves regular assessments during and after the treatment period to track symptom changes and any side effects.

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder